Toggle light / dark theme

Today, we have a guest article from Dr. Marion Tible, a scientist, and author over at the aging research-focused blog Long Long Life. What follows is an introduction to the senescent cell-clearing therapies known as senolytics, these therapies are poised to enter human trials and if successful could revolutionize how we treat age-related diseases.

What are senolytics?

Discovered in 2015 by a team from Mayo Clinic and the Scripps Research Institute in the United States, senolytics are a growing trend in the anti-aging community. They are very promising drugs in the fight against cellular senescence, a hallmark of aging.

Read more

During the recent Undoing Aging conference in Berlin, we worked with Anna Dobryukha from Komsomolskaya Pravda, one of the largest Russian publishing houses. We collaborated on a series of interviews, including this one with Dr. Jonathan Clark from the Babraham Institute.


The Undoing Aging conference, a collaboration between the SENS Research Foundation and Michael Greve’s Forever Healthy Foundation, took place on March 15–17 in Berlin, and it saw many researchers, advocates, investors, and other important members of the longevity community gather together to learn about the latest progress in rejuvenation biotechnology.

LEAF arranged a travel grant for Anna Dobryukha, one of the best Russian journalists writing about aging, longevity, and rejuvenation research, to join us, so it made sense to collaborate with her on the most interesting interviews. Anna works for Komsomolskaya Pravda, one of the largest Russian publishing houses, which has a newspaper, a radio station, and a website with over 40 million readers.

During the conference, we had the opportunity to interview Dr. Jonathan Clark, who has recently been focusing on skin aging and the interactions of collagen in this process. He is the head of the biological chemistry department at the Babraham Institute, where his group carries out aging research. Dr. Clark has some interesting research which he presented at the conference but which has yet to be published, this means that he could not tell us everything he had discovered in this interview, but don’t worry, we have agreed a follow-up interview with him once his data is published.

“Old age isn’t a battle,” she says, quoting Philip Roth, “old age is a massacre.” In the past few years, she has given up on screenings and scans. Not that she is lazy or suicidal. But at 76, she considers herself old enough to die. All the self-help books aimed at her age group tell her otherwise; they talk of “active ageing”, “productive ageing”, “anti-ageing”, even “reverse-ageing”, with a long life promised to anyone who makes an effort, regardless of factors such as genetics or poverty. But to her, ageing is “an accumulation of disabilities”, which no amount of physical activity or rigorous self-denial can prevent. If she has symptoms, she’ll have them investigated. But when a doctor tells her there could be an undetected problem of some kind, she won’t play along.


A great iconoclast has written a polemic about ageing that sends up New Age platitudes and is full of scepticism of the wellness industry.

Blake Morrison

Thu 12 Apr 2018 02.30 EDT Last modified on Fri 13 Apr 2018 19.10 EDT.

Peripheral Elevation of a #Klotho Fragment Enhances Brain Function and Resilience in Young, Aging, and α-Synuclein Transgenic Mice.


Klotho is a longevity factor associated with cognitive enhancement when genetically and widely overexpressed over the lifetime of mice. Leon et al. show that peripheral delivery of a klotho fragment, αKL-F, acutely enhances cognition and neural resilience in young, aging, and disease model mice, establishing its therapeutic relevance and dissecting its underlying mechanisms.

Read more

Happy birthday to dr. aubrey de grey bigsmile


How many biologists does it take to make nontrivial progress on an unsolved mathematical problem for the first time in nearly 70 years? The answer is one, at least if the biologist is Dr. Aubrey de Grey, the pioneer of the repair approach to aging.

Yes, you read that right. Today, in occasion of Dr. de Grey’s birthday, we’ve decided to take a short break from biology and rejuvenation to tell our readers about the recent scientific achievement of one of the world’s most famous biogerontologists—unexpectedly, but pleasantly so, in the field of mathematics.

The chromatic number of the plane

Y Combinator announces the first wave of support for biotech startups working on aging.


Earlier this year, the Y Combinator (YC) community showed interest in supporting biotechnology focused on healthspan and age-related disease. The YC community is an influential part of the Bay Area technology-focused industry in California. It was great to hear that it was planning to support biotech startups working on aging through its YC Bio program.

The first area we’re going to focus on is healthspan and age-related disease—we think there’s an enormous opportunity to help people live healthier for longer, and that it could be one of the best ways to address our healthcare crisis.

YC Bio launches in June with lab space for biotech startups